联化科技股份有限公司（以下简称"公司"）召开第九届董事会第四次会议， 会议以5票同意，0票反对，0票弃权的表决结果，审议并通过《关于2026年度日 常关联交易预计的议案》，关联董事王萍女士和樊小彬先生回避表决。此议案亦 经第九届董事会独立董事专门会议第一次会议审议通过，全体独立董事同意将本 议案提交董事会审议。 证券代码：002250 证券简称：联化科技 公告编号：2025-059 联化科技股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 根据《深圳证券交易所股票上市规则》有关规范关联交易的规定，以2025 年1-11月份日常关联交易实际发生额1,684.60万元为基础，对2026年度全年累计 发生的同类日常关联交易的总金额进行合理预计，预计总金额为3,600.00万元。 公司2026年度合计日常关联交易预计金额未超过公司最近一期经审计净资 产的5%，根据《深圳证券交易所股票上市规则》以及《公司章程》的规定，本 议案在公司董事会审批权限范围内，无需提交公司 ...

第九届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002250 证券简称：联化科技 公告编号：2025-058 联化科技股份有限公司 具体详见公司同日刊登于《证券时报》《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）的《关于2026年度日常关联交易预计的公告》（公告编号： 2025-059）。 特此公告。 联化科技股份有限公司董事会 二〇二五年十二月三十一日 联化科技股份有限公司（以下简称"公司"）第九届董事会第四次会议通知 于2025年12月26日以电子邮件方式通知各董事。会议于2025年12月30日在联化科 技会议室以现场与通讯表决相结合的方式召开。会议应出席董事7人，实际出席 董事7人。公司高级管理人员列席了本次会议，会议由董事长王萍女士召集和主 持，符合《公司法》《证券法》等法律法规、部门规章、规范性文件及《公司章 程》的有关规定。会议形成如下决议： 一、会议以5票同意，0票反对，0票弃权的表决结果，审议并通过《关于2026 年度日常关联交易预计的议案》，关联董事王萍女士和樊小彬先生回避表决。 ...

Market Overview - The agricultural chemical sector experienced a decline of 1.48% on December 29, with Runfeng Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Stock Performance - Notable gainers in the agricultural chemical sector included: - Beisimei (300796) with a closing price of 8.76, up 1.39% on a trading volume of 54,300 shares and a turnover of 47.32 million yuan [1] - Nongxin Technology (001231) at 22.72, up 1.38% with a trading volume of 25,600 shares and a turnover of 57.69 million yuan [1] - Baiao Chemical (603360) at 31.68, up 1.38% with a trading volume of 120,500 shares and a turnover of 381 million yuan [1] - Conversely, significant decliners included: - Runfeng Co., Ltd. (301035) at 66.10, down 5.58% with a trading volume of 34,100 shares and a turnover of 228 million yuan [2] - Yanhai Co., Ltd. (000792) at 27.69, down 4.48% with a trading volume of 1,063,600 shares and a turnover of 2.994 billion yuan [2] - Zhejiang Agricultural Co., Ltd. (002758) at 9.83, down 3.91% with a trading volume of 170,200 shares [2] Capital Flow - The agricultural chemical sector saw a net outflow of 637 million yuan from institutional investors, while retail investors contributed a net inflow of 407 million yuan [2] - Key stocks with notable capital flows included: - Yuntianhua (600096) with a net inflow of 12.8 million yuan from institutional investors [3] - Baiao Chemical (603360) with a net inflow of 18.96 million yuan from institutional investors [3] - Runfeng Co., Ltd. (301035) had a net outflow of 30.6 million yuan from institutional investors but a net inflow of 20.74 million yuan from retail investors [3]

Group 1 - The company is currently in the technical improvement phase for its lithium hexafluorophosphate project, focusing on systematic process development and continuous improvement to enhance product competitiveness [2] - The company responded to an investor inquiry regarding whether its lithium hexafluorophosphate products are used for in-house electrolyte testing and applications [2] - The company did not provide specific information on whether its production costs are superior to industry levels [2]

Core Viewpoint - The company is expanding its pharmaceutical business by diversifying into emerging sectors while consolidating its established small molecule CDMO services [1] Group 1: Business Expansion - The company is focusing on expanding its service areas in the pharmaceutical sector [1] - It is investing heavily in new business areas such as peptide products, radiopharmaceutical-related CDMO, animal health CDMO, generic drug intermediates and APIs, and cosmetic raw materials [1] Group 2: Technical Capabilities - The company's technical capabilities have evolved from traditional small molecules to include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides [1] - It has experience in delivering from linker grams to hundreds of grams, enabling the design and optimization of synthetic routes for clients [1] - This capability supports the transition of early clinical projects [1]

南财智讯12月22日电，联化科技在投资者关系活动中表示，公司目前暂无以二级市场融资为核心的资本 运作计划。2025年前三季度经营活动产生的现金流量净额约9亿元，自有资金足以支撑当前资本开支。 近期投资重点集中于临海基地与马来西亚基地建设，未来将根据战略项目需要及市场环境审慎评估是否 启动新的融资安排。 ...

Core Viewpoint - Company focuses on enhancing its core businesses in agricultural protection and pharmaceutical CDMO through overseas base expansion and R&D innovation, while steadily advancing its new energy business for long-term development [2] Group 1: Investor Relations Activity - On December 19, the company held an investor relations activity with five institutions, including Guohai Securities and Nomura Asset Management, discussing key issues such as agricultural protection business layout, pharmaceutical CDMO development, R&D innovation direction, and capital operation plans [1] - The meeting was attended by the company's Senior Vice President and Secretary of the Board, Chen Feibiao, and Securities Affairs Representative Dai Yiyi [1] Group 2: Agricultural Protection Business - The company plans to enhance its overseas base layout, establishing Malaysia as a second overseas base for a differentiated supply chain, collaborating with production bases in China and the UK [1] - The agricultural protection industry is highly concentrated, and the company has formed long-term strategic partnerships with several international agrochemical companies, covering all stages of the product lifecycle [1] Group 3: Pharmaceutical Business - The pharmaceutical business is expanding its coverage and deepening cooperation, focusing on products under patent protection [1] - The company aims for steady long-term growth by enhancing technical capabilities to strengthen customer cooperation [1] Group 4: R&D Innovation - The company is expanding into emerging fields such as peptide and radioactive drugs, while continuing to develop small molecule CDMO and starting materials [1] - The team has experience in delivering peptide and PEG linker products, optimizing synthesis routes based on customer needs [1] Group 5: CDMO Core Competitiveness - The company's core competitiveness lies in strong technological innovation, high safety and environmental standards, efficient production management, and a strict quality assurance system [1] - These advantages have earned recognition from leading global agricultural and pharmaceutical companies, ensuring stable and long-term cooperation [1] Group 6: Capital Operation - Currently, the company has no plans for secondary market financing, focusing capital expenditures on the construction of coastal and Malaysian bases [1] - As of the first three quarters of 2025, the company reported a net cash flow from operating activities of approximately 900 million yuan, sufficient to support planned capital expenditures [1] Group 7: New Energy Business - The company primarily sells LiFSI and electrolyte products, while improving the technology for lithium hexafluorophosphate [1] - It is expected that the new energy business will achieve significant revenue breakthroughs in 2025, leveraging its R&D and production advantages in fine chemicals [1]

每经AI快讯，联化科技（SZ 002250，收盘价：12.19元）发布公告称，2025年12月19日，联化科技接受 国海证券等投资者调研，公司高级副总裁、董秘陈飞彪，证券事务代表戴依依参与接待，并回答了投资 者提出的问题。 截至发稿，联化科技市值为110亿元。 每经头条（nbdtoutiao）——大洗牌！AI手机大战开启，豆包率先放大招！苹果、谷歌"慢半拍"？业 内：苹果是"最保守的大玩家" （记者 曾健辉） 2025年1至6月份，联化科技的营业收入构成为：工业占比99.64%，其他业务占比0.36%。 ...

Group 1: Agricultural Protection Business - The agricultural protection business currently accounts for a significant portion of the company's revenue, with plans for future development focusing on maintaining steady growth in this concentrated industry [1] - The company has established long-term strategic partnerships with multiple international agricultural companies, covering all stages of the product lifecycle [1] - The company has production bases across China and an overseas base in the UK, with plans to establish Malaysia as a second overseas base to enhance supply chain differentiation [1] Group 2: Pharmaceutical Business Development - The pharmaceutical business is rapidly developing, with a focus on attracting new strategic and high-viscosity clients [2] - The company has formed stable commercial relationships with several high-quality domestic and international clients, expanding its business cooperation scope [2] - Future growth in the pharmaceutical sector is expected as the company continues to promote products under patent protection and enhance its technical capabilities [2] Group 3: Research and Development Directions - The company is expanding its R&D efforts from traditional small molecule drugs to include amino acids, peptides, and other advanced drug delivery systems [3] - The team is focused on accelerating the transition of early clinical projects for clients, providing diverse linker synthesis services for ADC/PROTAC drugs [3] - These new directions are anticipated to broaden the company's CDMO service offerings and enable the acquisition of more projects [3] Group 4: CDMO Capabilities and Client Relationships - The company emphasizes enhancing its technical innovation, safety standards, production management, and quality assurance systems to meet client needs [4] - A strong intellectual property confidentiality system and a commitment to integrity have earned the company recognition from leading global agricultural and pharmaceutical clients [4] - The selection of suppliers by international clients is based on comprehensive evaluations of technology, regulations, environmental standards, and quality, leading to stable and long-term partnerships [5] Group 5: Capital Operations and Financial Outlook - Currently, the company has no plans for capital operations focused on secondary market financing, with recent capital expenditures directed towards the construction of coastal and Malaysian bases [5] - The net cash flow from operating activities for the first three quarters of 2025 was approximately 9 billion, sufficient to support planned capital expenditures [5] - Future financing plans will be evaluated based on strategic investment needs and market conditions [5] Group 6: New Energy Business - The company primarily focuses on the sales of lithium hexafluorophosphate and electrolyte products, with ongoing technical improvements in the lithium hexafluorophosphate project [5] - Revenue from the new energy business is expected to break through in 2025, with plans to deepen market penetration and optimize the supply chain [5]

Core Viewpoint - The company is focusing on a major client strategy in its pharmaceutical business, primarily through a CDMO business model, and has established partnerships with several leading global pharmaceutical companies [1] Group 1: Business Strategy - The company has adopted a CDMO (Contract Development and Manufacturing Organization) business model as its main approach in the pharmaceutical sector [1] - The company is actively expanding its client base by targeting strategic and high-viscosity clients [1] Group 2: Client Relationships - The pharmaceutical division has established stable commercial relationships with a number of high-quality domestic and international clients [1] - The scope of business cooperation is continuously expanding, and the depth of collaboration is increasing [1] Group 3: Future Growth Potential - The company is aligning its product pipeline with the business pipelines of its clients, which will enhance its technical capabilities [1] - Long-term growth in the pharmaceutical business is anticipated as the company continues to promote products during the patent periods of its clients [1]